MAIA Biotechnology grants director 32,774 options
The director's options vested 100% on the grant date and were exercisable beginning that day, with an expiration date of September 30, 2036.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MAIA Biotechnology, Inc. reported a grant of 32,774 stock options to director Steven M. Chaouki on September 30, 2026. The options represent the right to buy common stock at an exercise price of $1.18 per share. They vest 100% on the grant date and are exercisable beginning that date, with an expiration date of September 30, 2036.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options F1 | 32,774 | $0.00 | $0.00 |
Footnotes (1)
- F1. The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Key Figures
Key Terms
Stock Options financial
2021 Equity Incentive Plan financial
vest financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many stock options did MAIA director Steven M. Chaouki receive?
Under which plan were MAIA's options granted?
AI-generated analysis. How Rhea-AI works. Not financial advice.